男子淋菌性尿道炎に対するFleroxacinの細菌学的・臨床学的検討

Abstract

FLRXの抗菌力は, NFLXやOFLXと比べMICで1～2管程度の差であり, ほぼ同程度と思われる.しかし血中半減期が長いことは, 淋菌性尿道炎治療における単回投与療法にはより適している.本治験では, 臨床的に1日1回300 mgの単回投与と1日1回200 mgの連続投与との間で, 有効性に差異は見られなかった.クラミジアを合併した1例で無効例があったが, この菌株に対するFLRXのMICは治療前で0.78 μg/ml, 治療後で1.56 μg/mlと一管高くなっている.この菌株に対する他の新キノロン剤のMICでも, FLRX同様治療後にすべて高くなっていた

We performed basic and clinical studies on the effects of a new oral antimicrobial agent, fleroxacin (FLRX), a new quinolone derivative in male gonococcal urethritis. The antibacterial activity of FLRX against clinical strains of Neisseria gonorrhoeae was roughly comparable to that of norfloxacin and ofloxacin. FLRX was administered to 58 males with gonococcal urethritis. Two different schedules of administration were adopted. One was a single-dose of 300 mg given orally (17 cases) and the other was the oral administration of 200 mg once a day for 3 to 10 days (41 cases). Clinical evaluation was made according to the criteria of the Japanese UTI Committee. The overall efficacy rate was 98% (49/50). For complications of Chlamydia trachomatis (11 cases), the efficacy rate was 90.9% (10/11). No subjective or objective adverse reaction occurred.